

ASTRAZENECA PLC  
Form 6-K  
May 10, 2012

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For April 2012

Commission File Number: 001-11960

AstraZeneca PLC

2 Kingdom Street, London W2 6BD

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_\_

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-\_\_\_\_\_

AstraZeneca PLC

INDEX TO EXHIBITS

1. Press release entitled, “Repurchase of shares in AstraZeneca PLC”, dated 2 April 2012.
  2. Press release entitled, “Transparency Directive Voting Rights and Capital”, dated 2 April 2012.
  3. Press release entitled, “Transaction by Person Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4”, dated 2 April 2012.
  4. Press release entitled, “Transaction by Person Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4”, dated 2 April 2012.
  5. Press release entitled, “Transaction by Persons Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4”, dated 2 April 2012.
  6. Press release entitled, “Transaction by Person Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4”, dated 2 April 2012.
  7. Press release entitled, “Repurchase of shares in AstraZeneca PLC”, dated 3 April 2012.
  8. Press release entitled, “AstraZeneca and Amgen announce collaboration to jointly develop and commercialise clinical-stage inflammation portfolio”, dated 3 April 2012.
  9. Press release entitled, “Repurchase of shares in AstraZeneca PLC”, dated 4 April 2012.
  10. Press release entitled, “Repurchase of shares in AstraZeneca PLC”, dated 5 April 2012.
  11. Press release entitled, “Repurchase of shares in AstraZeneca PLC”, dated 10 April 2012.
  12. Press release entitled, “Repurchase of shares in AstraZeneca PLC”, dated 11 April 2012.
  13. Press release entitled, “Annual Information Update”, dated 11 April 2012.
  14. Press release entitled, “Repurchase of shares in AstraZeneca PLC”, dated 12 April 2012.
-

15. Press release entitled, "Repurchase of shares in AstraZeneca PLC", dated 13 April 2012.
16. Press release entitled, "Repurchase of shares in AstraZeneca PLC", dated 16 April 2012.
17. Press release entitled, "Repurchase of shares in AstraZeneca PLC", dated 17 April 2012.
18. Press release entitled, "Repurchase of shares in AstraZeneca PLC", dated 18 April 2012.
19. Press release entitled, "Repurchase of shares in AstraZeneca PLC", dated 19 April 2012.
20. Press release entitled, "Repurchase of shares in AstraZeneca PLC", dated 20 April 2012.
21. Press release entitled, "Forxiga (dapagliflozin) receives positive CHMP opinion in the European Union for the treatment of type 2 diabetes", dated 20 April 2012.
22. Press release entitled, "Repurchase of shares in AstraZeneca PLC", dated 23 April 2012.
23. Press release entitled, "AstraZeneca to Acquire Ardea Biosciences for \$1 Billion (net of existing cash) including lead product lesinurad in Phase III development for gout", dated 23 April 2012.
24. Press release entitled, "Repurchase of shares in AstraZeneca PLC", dated 24 April 2012.
25. Press release entitled, "Repurchase of shares in AstraZeneca PLC", dated 25 April 2012.
26. Press release entitled, "AstraZeneca PLC Notice of Results", dated 25 April 2012.
27. Press release entitled, "AstraZeneca PLC First Quarter Results 2012", dated 26 April 2012.
28. Press release entitled, "David Brennan to retire as AstraZeneca's Chief Executive Officer", dated 26 April 2012.

Edgar Filing: ASTRAZENECA PLC - Form 6-K

29. Press release entitled, "Repurchase of shares in AstraZeneca PLC", dated 26 April 2012.
30. Press release entitled, "AstraZeneca PLC Annual General Meeting, dated 26 April 2012.
31. Press release entitled, "Repurchase of shares in AstraZeneca PLC", dated 27 April 2012.
32. Press release entitled, "Transactions by Persons Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4", dated 27 April 2012.
33. Press release entitled, "Repurchase of shares in AstraZeneca PLC", dated 30 April 2012.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 10 May 2012

By: /s/ Claire-Marie O'Grady  
Name: Claire-Marie O'Grady  
Title: Deputy Company Secretary

Item 1

REPURCHASE OF SHARES IN ASTRAZENECA PLC

Further to the announcement of its irrevocable, non-discretionary share repurchase programme for the period 5 March 2012 to 11 May 2012, AstraZeneca PLC announced that under the terms of that programme it purchased for cancellation 305,437 ordinary shares of AstraZeneca PLC at a price of 2785 pence per share on 30 March 2012. Upon the cancellation of these shares, the number of shares in issue will be 1,273,493,566.

A C N Kemp  
Company Secretary  
2 April 2012

---

Item 2

Transparency Directive

Voting Rights and Capital

The following notification is made in accordance with the UK Financial Services Authority Disclosure and Transparency Rule 5.6.1. On 31 March 2012 the issued share capital of AstraZeneca PLC with voting rights is 1,273,930,953 ordinary shares of US\$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,273,930,953.

The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the Financial Services Authority's Disclosure and Transparency Rules.

A C N Kemp  
Company Secretary  
2 April 2012

---

Item 3

Transaction by Person Discharging Managerial Responsibilities  
Disclosure Rule DTR 3.1.4

The interest of David Brennan, a Director of the Company, in AstraZeneca PLC ordinary shares, has changed as detailed below.

On 30 March 2012, Mr Brennan was granted awards under the terms of the AstraZeneca Investment Plan (AZIP) and the AstraZeneca Performance Share Plan (AZPSP) over the Company's ordinary shares. A summary of these plans can be found in the AstraZeneca Annual Report and Form 20-F Information 2011 which is available on the Company's website [www.astrazeneca.com](http://www.astrazeneca.com).

Name	Shares awarded under AZIP	Shares awarded under AZPSP	Award price per share
David Brennan	22,219	133,318	2805p

The AZIP award is subject to a four-year performance period (1 January 2012 to 31 December 2015) and a subsequent four-year holding period (1 January 2016 to 31 December 2019). The performance hurdle that applies to the AZIP award relates to dividends and dividend cover.

The AZPSP award is subject to a three-year performance period (1 January 2012 to 31 December 2014). The performance measures that apply to the AZPSP award relate to relative total shareholder return and cash flow.

Mr Brennan has interests in both the ordinary shares and the American Depositary Shares (ADSs) of AstraZeneca PLC. One ADS equals one ordinary share.

As a result of these transactions, Mr Brennan has an interest in 734,270 ordinary shares and 83,344 AstraZeneca ADSs, which together represent approximately 0.06% of the Company's issued ordinary capital.

A C N Kemp  
Company Secretary  
2 April 2012



Item 4

Transaction by Person Discharging Managerial Responsibilities  
 Disclosure Rule DTR 3.1.4

The interest of Simon Lowth, a Director of the Company, in AstraZeneca PLC ordinary shares, has changed as detailed below.

On 30 March 2012, Mr Lowth was granted awards under the terms of the AstraZeneca Investment Plan (AZIP) and the AstraZeneca Performance Share Plan (AZPSP) over the Company's ordinary shares. A summary of these plans can be found in the AstraZeneca Annual Report and Form 20-F Information 2011 which is available on the Company's website [www.astrazeneca.com](http://www.astrazeneca.com).

Name	Shares awarded under AZIP	Shares awarded under AZPSP	Award price per share
Simon Lowth	11,764	70,588	2805p

The AZIP award is subject to a four-year performance period (1 January 2012 to 31 December 2015) and a subsequent four-year holding period (1 January 2016 to 31 December 2019). The performance hurdle that applies to the AZIP award relates to dividends and dividend cover.

The AZPSP award is subject to a three-year performance period (1 January 2012 to 31 December 2014). The performance measures that apply to the AZPSP award relate to relative total shareholder return and cash flow.

As a result of these awards, Mr Lowth has an interest in 291,399 ordinary shares which represents approximately 0.02% of the Company's issued ordinary capital.

A C N Kemp  
 Company Secretary  
 2 April 2012

## Item 5

Transactions by Persons Discharging Managerial Responsibilities  
Disclosure Rule DTR 3.1.4

On 30 March 2012, the following individuals, who are all persons discharging managerial responsibilities, were each granted awards under the terms of the AstraZeneca Investment Plan (AZIP) and the AstraZeneca Performance Share Plan (AZPSP) over the Company's ordinary shares, or, in the case of David Smith, Lynn Tetrault and Tony Zook, over the Company's American Depositary Shares (ADSs). One ADS equals one ordinary share. A summary of these plans can be found in the AstraZeneca Annual Report and Form 20-F Information 2011 which is available on the Company's website [www.astrazeneca.com](http://www.astrazeneca.com).

Name	Shares awarded under AZIP	Shares awarded under AZPSP	Award price per share
Katarina Ageborg	3,291	19,747	2805p
Martin Mackay	16,764	100,588	2805p
Jeff Pott	8,975	53,850	2805p
David Smith	8,306	49,841	\$44.82
Lynn Tetrault	7,194	43,168	\$44.82
Tony Zook	16,669	100,014	\$44.82

The AZIP award is subject to a four-year performance period (1 January 2012 to 31 December 2015) and a subsequent four-year holding period (1 January 2016 to 31 December 2019). The performance hurdle that applies to the AZIP award relates to dividends and dividend cover.

The AZPSP award is subject to a three-year performance period (1 January 2012 to 31 December 2014). The performance measures that apply to the AZPSP award relate to relative total shareholder return and cash flow.

A C N Kemp  
Company Secretary  
2 April 2012

Item 6

Transaction by Person Discharging Managerial Responsibilities  
Disclosure Rule DTR 3.1.4

The interest of Lynn Tetrault, a person discharging managerial responsibility, in the shares of AstraZeneca PLC has changed as detailed below. Lynn Tetrault has interests in the American Depositary Shares (ADSs) of AstraZeneca PLC. One ADS equals one ordinary share.

On 30 March 2012, Mrs Tetrault exercised an option over 73,926 ADSs at an option price of \$33.39 per ADS.

Following the exercise, Mrs Tetrault sold 63,516 of the 73,926 ADSs so acquired at a price of \$44.52 per ADS.

On 30 March 2012, Mrs Tetrault also sold 12,868 ADSs at a price of \$44.68 per ADS.

A C N Kemp  
Company Secretary  
2 April 2012

---

Item 7

REPURCHASE OF SHARES IN ASTRAZENECA PLC

Further to the announcement of its irrevocable, non-discretionary share repurchase programme for the period 5 March 2012 to 11 May 2012, AstraZeneca PLC announced that under the terms of that programme it purchased for cancellation 303,743 ordinary shares of AstraZeneca PLC at a price of 2801 pence per share on 2 April 2012. Upon the cancellation of these shares, the number of shares in issue will be 1,273,627,210.

A C N Kemp  
Company Secretary  
3 April 2012

---

ITEM 8

ASTRAZENECA AND AMGEN ANNOUNCE COLLABORATION TO JOINTLY  
DEVELOP AND COMMERCIALISE CLINICAL-STAGE INFLAMMATION PORTFOLIO

Collaboration Comprises Five Monoclonal Antibodies  
Brodalumab (AMG 827) Phase 3 Trial Planned in 2012

AstraZeneca and Amgen today announced an agreement to jointly develop and commercialise five monoclonal antibodies from Amgen's clinical inflammation portfolio: AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab (AMG 827).

The companies believe all the molecules have novel profiles and offer the potential to deliver important treatments across multiple indications in inflammatory diseases. The collaboration will provide Amgen with additional resources to optimally progress its portfolio, and Amgen will benefit from the strong respiratory, inflammation and asthma development expertise of MedImmune, AstraZeneca's biologics arm. The collaboration will also capitalise on AstraZeneca's global commercial reach in respiratory and gastrointestinal diseases. The agreement does not include certain territories previously partnered by Amgen for brodalumab with Kyowa Hakko Kirin and AMG 557 with Takeda.

Under the terms of the agreement, AstraZeneca will make a one-time \$50 million upfront payment and the companies will share both costs and profits. Based on current plans, approximately 65 percent of costs for the 2012-2014 period will be funded by AstraZeneca. Thereafter, the companies will split costs equally. Amgen will book sales globally and will retain a low single-digit royalty for brodalumab and a mid single-digit royalty for the rest of the portfolio after which the companies will share profits equally.

AstraZeneca will lead the development and commercialisation strategy of AMG 139, AMG 157 and AMG 181, while Amgen will lead the development and commercialisation strategy of brodalumab and AMG 557. Each development and commercialisation lead will be under the oversight of joint governing bodies. For brodalumab, commercial promotion will be split. Amgen will promote in dermatology indications in the US and Canada, and in rheumatology indications in US, Canada and Europe. AstraZeneca will promote in respiratory and, initially, in dermatology indications of brodalumab across all territories outside of the US, Canada and those markets where Amgen has existing partnerships. Allocation of promotion rights for other territories, indications and molecules will be agreed later between the companies.

"We are delighted to join forces with Amgen in developing and commercialising these novel clinical-stage assets that add value to our pipeline and build on our expertise in biologics. This creative collaboration will make the most of both companies' respective capabilities, including AstraZeneca's extensive global reach, to help bring these potentially innovative treatment options for a variety of respiratory and inflammatory diseases to patients around the world," said David Brennan, Chief Executive Officer, AstraZeneca.

"We are very excited at the prospect of collaborating with a well-respected organisation like AstraZeneca to advance our inflammation pipeline," said Kevin Sharer, Chairman and CEO at Amgen. "We believe this collaboration has the potential to bring more therapies to patients sooner, across more geographic areas. We are impressed with AstraZeneca's extensive experience in developing and launching products in the respiratory and gastroenterology areas, and believe this collaboration is an opportunity to work with a partner that has leading regulatory and commercial expertise in inflammation indications."



#### About the inflammation portfolio included in the agreement

Under the agreement, the companies will jointly develop and commercialise the following five monoclonal antibodies (immunoglobulin proteins that have been synthesized using recombinant DNA technology) from Amgen's clinical-stage portfolio:

- Brodalumab (AMG 827) is a human monoclonal antibody that binds to and blocks signaling via the IL-17 receptor. Brodalumab is currently being investigated for the treatment of psoriasis (completed Phase 2 and planned Phase 3), psoriatic arthritis (Phase 2) and asthma (Phase 2).
- AMG 139 is a human monoclonal antibody that neutralises IL-23 interaction with its receptor while sparing IL-12. It is being investigated as a treatment for a variety of inflammatory disorders. AMG 139 is being investigated in Phase 1 for Crohn's disease, with lifecycle possibilities in psoriasis and other inflammatory conditions.
- AMG 181 is a human monoclonal antibody to alpha4/beta7 that blocks binding to MAdCAM-1. It is being investigated in Phase 1b trials for the treatment of ulcerative colitis and Crohn's disease.
- AMG 557 is a human monoclonal antibody that binds to B7 related protein (B7RP-1). It is being investigated in Phase 1b for its utility in autoimmune diseases such as systemic lupus erythematosus.
- AMG 157 is a human monoclonal antibody that blocks the interaction of thymic stromal lymphopoietin (TSLP) with the TSLP receptor. AMG 157 is being investigated in Phase 1b trials for its potential as a treatment for asthma.

#### About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit [www.amgen.com](http://www.amgen.com). Follow us on [www.twitter.com/amgen](http://www.twitter.com/amgen).

#### About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: [www.astrazeneca.com](http://www.astrazeneca.com).

#### AstraZeneca:

##### Media Enquiries

Sarah Lindgreen +44 20 7604  
8033

Esra Erkal-Paler +44 20 7604  
8030

##### Investor Enquiries UK

James Ward-Lilley +44 20 7604 mob: +44 7785 432613  
8122

Karl Hård +44 20 7604 mob: +44 7789 654364  
8123

Edgar Filing: ASTRAZENECA PLC - Form 6-K

Nicklas Westerholm +44 20 7604 8124 mob: +44 7585 404950

Investor Enquiries US  
Ed Seage +1 302 886 4065 mob: +1 302 373 1361  
Jorgen Winroth +1 212 579 0506 mob: +1 917 612 4043

Amgen:  
Media Enquiries  
Christine Regan +1 805-447-5476

Investor Enquiries  
Arvind Sood +1 805-447-1060

3 April 2012

- ENDS -

Page 2/2

---



Item 9

REPURCHASE OF SHARES IN ASTRAZENECA PLC

Further to the announcement of its irrevocable, non-discretionary share repurchase programme for the period 5 March 2012 to 11 May 2012, AstraZeneca PLC announced that under the terms of that programme it purchased for cancellation 299,928 ordinary shares of AstraZeneca PLC at a price of 2838 pence per share on 3 April 2012. Upon the cancellation of these shares, the number of shares in issue will be 1,273,618,531.

A C N Kemp  
Company Secretary  
4 April 2012

---

Item 10

REPURCHASE OF SHARES IN ASTRAZENECA PLC

Further to the announcement of its irrevocable, non-discretionary share repurchase programme for the period 5 March 2012 to 11 May 2012, AstraZeneca PLC announced that under the terms of that programme it purchased for cancellation 303,195 ordinary shares of AstraZeneca PLC at a price of 2807 pence per share on 4 April 2012. Upon the cancellation of these shares, the number of shares in issue will be 1,273,444,803.

A C N Kemp  
Company Secretary  
5 April 2012

---

Item 11

REPURCHASE OF SHARES IN ASTRAZENECA PLC

Further to the announcement of its irrevocable, non-discretionary share repurchase programme for the period 5 March 2012 to 11 May 2012, AstraZeneca PLC announced that under the terms of that programme it purchased for cancellation 306,488 ordinary shares of AstraZeneca PLC at a price of 2776 pence per share on 5 April 2012. Upon the cancellation of these shares, the number of shares in issue will be 1,273,171,200.

A C N Kemp  
Company Secretary  
10 April 2012

---

Item 12

REPURCHASE OF SHARES IN ASTRAZENECA PLC

Further to the announcement of its irrevocable, non-discretionary share repurchase programme for the period 5 March 2012 to 11 May 2012, AstraZeneca PLC announced that under the terms of that programme it purchased for cancellation 305,177 ordinary shares of AstraZeneca PLC at a price of 2788 pence per share on 10 April 2012. Upon the cancellation of these shares, the number of shares in issue will be 1,272,934,176.

A C N Kemp  
Company Secretary  
11 April 2012

---

Item 13

ASTRAZENECA PLC  
ANNUAL INFORMATION UPDATE

As required under the Prospectus (Directive 2003/71/EC) Regulations 2005 and paragraph 5.2 of the Prospectus Rules, and following publication of the Annual Report and Form 20-F Information on 26 March 2012, AstraZeneca PLC is presenting its Annual Information Update in relation to information that has been published or made available to the public between 08 April 2011 and 10 April 2012.

This Annual Information Update is also being made available on the Investors section of our website, [www.astrazeneca.com](http://www.astrazeneca.com).

The information referred to in this Annual Information Update was correct at the time it was published but may now be out of date.

1. Announcements made via a RIS